San Diego, CA – Cortechs.ai, a leader in advanced medical imaging AI, announced a new collaboration with deepc, the premier platform provider for seamless integration of medical imaging AI solutions into clinical workflows. Through this partnership, Cortechs.ai’s trusted portfolio—including NeuroQuant®, NeuroQuant® MS, NeuroQuant® Brain Tumor, and OnQ™ Prostate—is now available via the deepcOS® platform, marking the first time these clinically-validated solutions are completely integrated into a radiology AI platform.
Unlocking Broader Access to Clinically Proven Tools
Cortechs.ai’s products are widely used across the United States and have earned clinical recognition through the assignment of Category III CPT codes for AI-assisted quantitative brain MRI. These codes not only reflect regulatory and clinical confidence in the technology but also signal a broader market readiness for AI solutions that demonstrate measurable value—both in clinical efficacy and healthcare reimbursement. As the first platform to completely integrate these tools outside Cortechs.ai’s own ecosystem, deepcOS® enables broader access to this validated technology across global healthcare systems, including those in Europe that are increasingly focused on demonstrating real-world AI impact.
Empowering Clinicians Through Integrated AI
The integration of Cortechs.ai’s solutions into deepcOS®, a vendor-neutral and enterprise-grade AI platform, allows hospitals and radiology centers to seamlessly deploy advanced imaging applications that support early detection, improved diagnosis, and monitoring of neurological diseases and cancer.
Cortechs.ai’s flagship offerings include:
- NeuroQuant® and NeuroQuant® MS: Automated brain segmentation and volumetric analysis that aid in the early detection and monitoring of neurodegenerative diseases, such as Alzheimer’s and Multiple Sclerosis.
- NeuroQuant® Brain Tumor: Quantitative imaging analysis to assist clinicians in evaluating brain tumor progression.
- OnQ™ Prostate: Enhances prostate MRI interpretation, enabling more precise detection and assessment of prostate cancer.
These solutions are now available via deepcOS®, delivering rapid deployment, regulatory compliance, and robust clinical validation within a single, scalable platform.
A Shared Vision for Scalable, Secure Clinical AI
Through this partnership, deepc and Cortechs.ai are demonstrating the value of interoperability and innovation in clinical practice. The collaboration underscores a shared commitment to transforming radiology workflows, reducing diagnostic burden, and enabling personalized care through scalable, secure AI integration.
“This partnership with deepc represents a pivotal step in expanding the reach of our AI-powered solutions to radiologists globally. By integrating with deepcOS®, we are accelerating the delivery of precise, data-driven insights that clinicians can trust through a premier partnership—ultimately improving outcomes for patients facing neurological and oncological conditions.” – Kyle Frye, CEO of Cortechs.ai
“We’re proud to be the first platform to offer Cortechs.ai’s advanced tools to the broader global market. This collaboration embodies deepc’s mission to deliver clinically meaningful AI that scales across health systems, supports reimbursement readiness, and improves patient care.” – Dr. Franz Pfister, CEO and Co-founder of deepc.
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.
About deepc
deepc has developed the radiology AI platform deepcOS®, providing clinicians with effortless access to a myriad of globally approved, regulatory-leading AI solutions for more than 80 clinical indications, delivering more efficient workflows, and offering radiologists assistance in their daily routine. With its rigorous validation of vendor-neutral AI solutions using large-scale independent data, as well as offering a practical evaluation of AI solutions on local clinical data, deepc ensures that radiologists benefit from the best AI solutions that meet their unique requirements. deepc enables easy and fast installation and end-to-end integration to make access to AI effortless in any clinical setting.
